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Sphingosine-1-phosphate–induced oxygen free
radical generation in smooth muscle cell migration
requires G12/13 protein-mediated
phospholipase C activation
Eliza Roztocil, BS, Suzanne M. Nicholl, PhD, and Mark G. Davies, MD, PhD, Rochester, NY
Background: Sphingosine-1-phosphate (S-1-P) is a bioactive sphingolipid that stimulates the migration of vascular
smooth muscle cell (VSMC) through G-protein coupled receptors; it has been shown to activate reduced nicotinamide
dinucleotide phosphate hydrogen (NAD[P]H) oxidase. The role of phospholipase C (PLC) in oxygen free radical
generation, and the regulation of VSMC migration in response to S-1-P, are poorly understood.
Methods: Rat arterial VSMC were cultured in vitro. Oxygen free radical generation was measured by fluorescent redox
indicator assays in response to S-1-P (0.1M) in the presence and absence of the active PLC inhibitor (U73122; U7,
10nM) or its inactive analog U73343 (InactiveU7, 10nM). Activation of PLC was assessed by immunoprecipitation and
Western blotting for the phosphorylated isozymes ( and ). Small interfering (si) RNA to the G-proteins Gi, Gq, and
G12/13 was used to downregulate specific proteins. Statistics were by one-way analysis of variance (n  6).
Results: S-1-P induced time-dependent activation of PLC- and PLC-; PLC- but not PLC- activation was blocked by
U7 but not by InactiveU7. PLC- activation was Gi-independent (not blocked by pertussis toxin, a Gi inhibitor, or
Gi2 and Gi3 siRNA) and Gq-independent (not blocked by glycoprotein [GP] 2A, a Gq inhibitor, or Gq siRNA).
PLC- activation and cell migration was blocked by siRNA to G12/13. Oxygen free radical generation induced by
S-1-P, as measured by dihydroethidium staining, was significantly inhibited by U7 but not by InactiveU7. Inhibition of
oxygen free radicals with the inhibitor diphenyleneiodonium resulted in decreased cell migration to S-1-P. VSMC
mitogen-activated protein kinase activation and VSMCmigration in response to S-1-P was inhibited by PLC- inhibition.
Conclusion: S-1-P induces oxygen free radical generation through a G12/13, PLC--mediated mechanism that
facilitates VSMC migration. To our knowledge, this is the first description of PLC-mediated oxygen free radical
generation as a mediator of S-1-P VSMC migration and illustrates the need for the definition of cell signaling to allow
targeted strategies in molecular therapeutics for restenosis. ( J Vasc Surg 2007;46:1253-9.)
Clinical Relevance: Activation of vascular smooth muscle cells by growth factors leads to cell proliferation and migration,
which are integral features of the healing response in a vessel that leads to the development of intimal hyperplasia after
bypass grafting, angioplasty, and stenting. Sphingosine-1-phosphate (S-1-P) is a common phospholipid, released from
activated platelets at sites of vessel injury. It is a G-protein–coupled receptor agonist that induces smooth muscle cell
migration, a key event in the development of intimal hyperplasia. Mechanisms of cell migration are not well defined, and
understanding the mechanisms of signal transduction is important in defining potential targets for therapeutic
intervention. The present study shows that S-1-P induces oxygen free radical generation through a G12/13,
PLC-–mediated mechanism that facilitates smooth muscle cell migration. Targeting choke points in cell signaling, such
as membrane G-proteins, is an attractive molecular target in developing therapeutic strategies to moderate restenosis.Activation of vascular smooth muscle cells (VSMC) by
growth factors leads to cell proliferation and migration,
which are integral features of the healing response in a
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than proliferation may be a primary biologic event leading
to intimal expansion, and the signaling leading to these
events is not fully defined.1
Sphingosine-1-phosphate (S-1-P) is a bioactive sphin-
golipid released in large amounts from activated platelets
that has been shown to have numerous biologic effects in a
large number of vascular cell types. It can act as a secondary
mediator for cell responses mediated by platelet-derived
growth factor (PDGF) and tissue plasminogen activator
(tPA).2,3 S-1-P has been identified as a chemoattractant for
VSMCs expressing G-protein–coupled receptors S-1-P1,
S-1-P2 and S-1-P3 receptors.2,4-7 S-1-P1 couples exclu-
sively to G-proteins of the Gi type, while S-1-P2 and
S-1-P3 couple to G-proteins of Gi, Gq, and G12/13
types.8,9
We have previously demonstrated that migration stimu-
lated by S-1-P in VSMCs involves PI3-kinase, extracellular
signal-regulated kinases 1/2 (ERK1/2), and p38MAPK.4-6
Others have shown that exogenous S-1-P will stimulate
oxygen free radical generation in association with an in-
crease in intracellular Ca2 concentration and an increase
in inositol phosphate production, reflecting activation of
phospholipase C (PLC).
Very limited data are available on the role of PLC- in
arterial injury. One report has shown that PLC- activities
are not significantly elevated24 hours of balloon injury in
the rat aorta, but PLC- activity has increased twofold by
14 days.10 Thus, it appears that PLC- activity is not
temporally associated with VSMC apoptosis or medial
VSMC proliferation but occurs during the periods of
VSMC migration and intimal expansion.1 S-1-P can acti-
vate PLC-, but its role in S-1-P–mediated VSMC migra-
tion and oxygen free radical generation activation is not
defined.
This study examined the role of the phospholipase C
signaling during oxygen free radical generation and VSMC
migration in response to S-1-P and tested the hypothesis
that G-protein–induced PLC activation mediates VSMC
migration through oxygen free radical–dependent mecha-
nisms.
METHODS
Experimental design. Aortic arterial VSMCs from
Sprague-Dawley rats (derived by the collagenase method),
passages 3 to 6, were cultured in vitro. Activation of PLC
was assessed by immunoprecipitation and Western blotting
for the phosphorylated isozymes ( and ). Small interfer-
ing (si) RNA to the G-proteins Gi, Gq, and G12/13
and adenoviral COOH-terminus -adrenergic receptor ki-
nase (-ARKct) was developed commercially and cells
transfected by a superlipofectamine method with appropri-
ate downregulation of targets before examination of
S-1-P–mediated PLC activation was confirmed.
Oxygen free radical generation was measured by fluores-
cent redox indicator assays in response to S-1-P (0.1M) in
the presence and absence of the active PLC inhibitor
(U73122; U7, 0.1-1000nM) or its inactive analog U73343(InactiveU7, 0.1-1000nM) and the nicotinamide dinucle-
otide phosphate hydrogen (NAD[P]H) oxidase inhibitor
diphenyleneiodonium (DPI, 10M). Cell migration in re-
sponse to S-1-P was tested in a wound assay and a Boyden
chamber assay under various inhibitory conditions.
Materials (available online only).
Western blotting. Cells were allowed to grow to 80%
confluence and starved for 48 hours. These cells were
stimulated with S-1-P alone (0.1M) and in the presence of
the inhibitors and harvested at time points from 0 to 60
minutes. At each time point, cells were washed once in
ice-cold Dulbecco phosphate buffered saline (DPBS) and
then mechanically removed in the presence of ice cold
kinase buffer (200 L; 25mM N-2-hydroxyethylpiperazine-
N=-2-ethanesulfonate [HEPES, pH 7.5], 10% glycerol,
5mM ethylenediaminetetraacetic acid, 5mM ethylenegly-
cotetraacetic acid, 150mM sodium chloride, 100mM ben-
zamidine, 0.1% 2-mercaptoethanol, 1% Triton X-100
[Union Carbide, Houston, Tex], 1mM pepstatin A, 2
mg/mL leupeptin, and 20 KIU/mL aprotinin).
Protein determinations were performed using a bicin-
chonic acid assay (Biorad Laboratories, Richmond, Calif)
with bovine serum albumen as the standard. Equal
amounts of protein lysates (20 g) were loaded onto a 10%
polyacrylamide gel separated by electrophoresis and then
transferred to a nitrocellulose membrane (Biorad).11 The
membrane was blocked in 5% nonfat milk.
The blot was then immunostained with antibodies
against either phosphorylated or total protein of interest.
Protein bands were visualized using an antimouse immu-
noglobulin G horseradish peroxidase-conjugated antibody,
followed by enhanced chemiluminescence (Amersham Bio-
science, Piscataway, NJ) using the manufacturer’s proto-
cols. Band intensity was measured using Gel-Imaging soft-
ware (Kodak, Rochester, NY). All experiments were
performed at least three times.
Immunoprecipitation. Time courses of S-1-P-in-
duced PLC- activation were performed in the presence
and absence of U73122 (100nM) and the Inactive U7
(100nM), as previously described.12 Total PLC- was im-
munoprecipitated from total cell extracts with a polyclonal
antibody (Upstate Biotechnology, Lake Placid, NY) ac-
cording to the manufacturer’s instructions. Immunocom-
plexes were then collected using protein A–Sepharose
beads (Pharmacia Biotech, Piscataway, NJ), washed several
times with Tween 20 (Union Carbide, Houston, Tex) in
DPBS (Cellgro, Herndon, Va), fractionated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis, and
probed with PY20 for tyrosine phosphorylation protein.
Small interfering RNA transfection. Pre-designed
2-hydroxyphytanoyl CoA lyase purified siRNA for gene
knockdown for Gi2 and Gi3 proteins were purchased
from Ambion Inc (Austin, Tex). VSMC of 50% confluence
in 60-mm plates were starved overnight in 4 mL of Opti-
MEM reduced serum medium (Gibco). Small interfering
RNA is transfected using Lipofectamine 2000 (Invitrogen
Inc, Carlsbad, Calif) following product protocol. Briefly,
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volume of 250 L of Opti-MEM for 5 minutes at room
temperature. It was then added to 250 L of Opti-MEM
containing 440 pmol of siRNA. The solution was mixed
gently and incubated for 20 minutes at room temperature,
after which it was added to the starved plates of VSMC. The
medium was changed after 4 to 6 hours of incubation. The
cells were then used 72 hours after transfection for PLC-
assays. Scrambled siRNA served as a control.
Using the methodologies described, we conducted
concentration dependent experiments with siRNA to
Gi2, Gi3, Gq, and G12/13 and demonstrated a
concentration dependent decrease in protein expression
that was specific for the G protein targeted without alter-
ing the expression of the other G subunits (Fig E1,
on-line only).
Adenoviral infection. Adenoviral vectors were con-
structed by Welgen Inc (Worcester, MA) using purified
plasmid encoding -ARKCT, obtained from Guthrie cDNA
Resource center. VSMC were plated at 70% confluence in
100-mm dishes and allowed to grow overnight. Recombi-
nant adenovirus was then added at the appropriate concen-
trations (-ARKCT; 100 MOI) in a reduced volume of
media (1.5 to 2 mL). After 48 hours of incubation, the
media was changed and cells were grown for an additional
24 hours. The cells were then used for PLC- assays.
Empty vector served as the control.
Dihydroethidium staining. Oxygen free radical gen-
eration was assayed using the oxygen free radical-sensitive
fluorescent dye dihydroethidium (DHE; 10 mol/L,
Sigma). S-1-P (100nM) was added to growth-arrested
VSMC in 24-well plates for variable times from 0 to 60
minutes. Dulbecco minimal essential medium (DMEM)
and angiotensin II were used as positive and negative
controls. Additional cells were examined in the presence of
DPI and apocynin to verify the role of NAD(P)H oxidase
activation by S-1-P. Plates were washed with PBS and then
incubated in the dark for 5 minutes in DMEM lacking
phenol red containing DHE (10 mol/L). After the incu-
bation, dishes were transferred to a fluorescent microscope
for photography. Intracellular reactive oxygen species gen-
eration was quantitated spectrophotometrically by mea-
surement of red fluorescent compound ethidium, which is
produced when DHE specifically reacts with intracellu-
lar O2
·–.
Cell migration. VSMC migration in response to
S-1-P (0.1M) was performed in the presence and absence
of U73122 (0.1 to 1000nM) and InactiveU7 (0.1 to
1000nM) using both the linear wound assay and the Boy-
den microchemotaxis chamber assays, as previously
described.5,6
Data and statistical analysis. All data are presented as
the mean  standard error of the mean. Statistical differ-
ences between groups were tested with a Kruskal-Wallis
nonparametric test with post hoc Dunn multiple compari-
son correction, where appropriate, using Instat 3 software
(Graph Pad Software Inc, San Diego, Calif). A value of P.05 was regarded as significant. Nonsignificant P values are
expressed as P  NS.
RESULTS
We examined the activation of PLC- and PLC-
isoforms in the VSMC by Western blotting in response to
S-1-P (0.1M). S-1-P–induced time-dependent activation
of PLC-, PLC-1, and PLC-2 was determined by phos-
phorylation of the respective protein relative to the total
unphosphosylated protein; peak activation of PLC-was at
10 minutes (Fig 1, A). PLC- activation was blocked by the
active PLC- inhibitor (U73122; U7) but not by Inac-
tiveU7; Fig 1, B). Neither inhibitor effected PLC- activa-
tion in response to S-1-P, suggesting specificity of the
inhibitor (Fig 1, B).
We have previously shown that S-1-P–mediated cell
Fig 1. Activation of phospholipase C- (PLC-). A, Sphin-
gosine-1-phosphate (S-1-P, 0.1M)–induced time-dependent ac-
tivation of PLC-, PLC-1, or PLC-2, as measured by Western
blotting. Maximal activation was at 5 minutes. PLC- activation
was blocked by U7 (10nM) but not by InactiveU7 (10nM). B, A
representative Western blot for PLC- is shown. C, Bar chart
shows quantification of S-1-P–induced time-dependent activation
of PLC-, PLC-1, or PLC-2, in the presence and absence of U7
and InactiveU7. Values are the mean  SEM of the ratio of the
phosphorylation of the respective protein relative to the total
unphosphorylated protein (n  6). P  .05 compared with the
control. DMEM, Dulbecco minimal essential medium.migration is dependent on G-protein coupled receptors.
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G. We, therefore, examined the role of G-proteins sub-
units G and G in the activation of PLC- by S-1-P using
a strategy of both pharmacologic and molecular inhibitors.
The activation of PLC- by S-1-P was Gi-independent
(not blocked by preincubation with pertussis toxin, a Gi
inhibitor, or transfection with Gi2 and Gi3 siRNA) and
Gq-independent (not blocked by preincubation with gly-
Fig 2. G-proteins and phospholipase C- (PLC-). A
was Gi-independent; that is, it was not blocked by per
interfering RNA (siRNA); and it was Gq-independen
Small interfering RNA to G12/13 blocked PLC-
-adrenergic receptor kinase (-	RKCT) also blocked PL
-actin as a loading control. B, The bar chart shows the q
also shows additional controls. Scrambled siRNA and
compared with control values. Values are the mean  S
relative to the total unphosphorylated PLC- (t-PLC-;
minimal essential medium; GP2A, glycoprotein 2A.coprotein-2A, a Gq inhibitor, or transfection with GqsiRNA; Fig 2). In contrast, siRNA to G12/13 blocked
PLC- activation (Fig 2). Scrambled siRNA for constructs
against Gi2, Gi3, and G12/13 were used as controls
and had no effect (data not shown). Adenoviral transfection
with -ARKCT, a G inhibitor, also blocked PLC- acti-
vation in response to S-1-P. Empty adenovirus had no
effect (Fig 2).
These data suggest that S-1-P mediates PLC- activa-
vation of PLC- by sphingosine-1-phosphate (0.1M)
toxin (PTx), a Gi inhibitor, or Gi2 and Gi3 small
blocked by GP-2A, a Gq inhibitor, or Gq siRNA).
ation. Transfection with adenoviral COOH-terminus
activation. Representative Western blots are shown with
fication of the experiments representative in Fig 1, A and
ty adenovirus did not significantly alter the response
f the ratio of the phosphorylation of PLC- (p-PLC-)
). *P  .05 compared with control. DMEM, Dulbecco, Acti
tussis
t (not
activ
C-
uanti
emp
EM o
n  6tion through a G12/13 and G–mediated pathway. To
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S-1-P–mediated cell migration. VSMC migration in re-
sponse to S-1-P in the wound and the Boyden chamber
assays of migration was inhibited by the PLC- inhibitor
U7 in a concentration-dependent manner and was unaf-
fected by similar concentrations of Inactive U7 (Fig 3, A
and B). Similarly when siRNA to G12/13 and transfec-
tion with -ARKCT were used, S-1-P mediated migration
was also significantly decreased (Fig 3, C).
Phospholipases can control the generation of oxygen
free radicals in cells, and oxygen free radicals are an impor-
tant mediator of cell signaling and cell migration. S-1-P–
induced oxygen free radical production as measured by
DHE staining (Fig E2, A to D online only) and estimated
by spectrophotometry was significantly inhibited by prein-
cubation with U7 but not with InactiveU7 (Fig E2, E
online only), suggesting that PLC- is involved in S-1-P–
mediated oxygen free radical activation. The increased
DHE staining was not seen in the presence of DMEM
alone and was significantly augmented in the presence of
Fig 3. Phospholipase C- (PLC-) and cell migration
sphingosine-1-phosphate (S-1-P; 0.1M) in both the wo
was inhibited by increasing concentrations of the PLC-
1 hour before each assay) but not the inactive analogue,
1 hour before each assay). C, Migration in response to S
small interfering RNA (siRNA) to G12/13 and aden
-	RKCT) transfection. The transfection of scrambled si
response to S-1-P (0.1M) in the Boyden chamber wa
hydrogen (NAD[P]H) oxidase inhibitor, diphenyleneio
*P  .05; **P  .01 compared with control.angiotensin II (Fig E2, F online only). S-1-P–mediatedaugmentation of DHE staining is inhibited by DPI, sug-
gesting that NAD(P)H oxidase is the enzyme responsible
for oxygen free radical generation in these VSMCs.
When siRNA to G12/13 and transfection with
-ARKCT were used, S-1-P–mediated augmentation of
DHE staining was also significantly decreased. VSMC mi-
gration in response to S-1-P in both the wound and the
Boyden chamber assays of migration was inhibited by the
NAD(P)H oxidase inhibitor DPI in a concentration-
dependent manner and unaffected by similar concentra-
tions of Inactive U7 (Fig 3, D).
We have previously shown that S-1-P will activate the
MAPKs ERK1/2 and p38MAPK and the kinase Akt. To
determine if the MAPK pathways were downstream of
PLC-, we examined ERK1/2 and p38MAPK activation in
the presence and absence of PLC- inhibitor. S-1-P in-
duced MEK1 and ERK1/2, and MKK3/6 and p38MAPK
activation was significantly inhibited by U7 but not by
InactiveU7 (Fig E3, A, B, and D, online only). Time-
dependent Akt phosphorylation was partially but not sig-
Vascular smooth muscle cell migration in response to
ssay and in (B) the Boyden chamber assays of migration
itor U7 (0.1 to 1000nM, preincubated with the cells for
tiveU7 (0.1 to 1000nM, preincubated with the cells for
(0.1M) in the Boyden chamber assay was inhibited by
COOH-terminus -adrenergic receptor kinase (adeno
or empty adenoviral had no effect. D, Cell migration in
inhibited by the nicotinamide dinucleotide phosphate
m chloride (DPI). Values are the mean SEM (n 6).. A,
und a
inhib
Inac
-1-P
oviral
RNA
s also
doniunificantly inhibited by U7; InactiveU7 had no effect
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PLC- is upstream of the MAPK ERK1/2 and p38MAPK.
DISCUSSION
S-1-P is a G-protein–coupled receptor agonist that can
stimulate VASMC migration. This migration is dependent
mainly on S-1-P1 (Gi mediated) and S-1-P3 (Gi, Gq,
and G12/13 mediated) receptors. Exogenous S-1-P will
stimulate oxygen free radical generation in association with
an increase in intracellular Ca2 concentration and an
increase in inositol phosphate production, reflecting activa-
tion of PLC. These three S-1-P–induced events can be
inhibited partially by pertussis toxin and markedly by
U73122, a PLC inhibitor, and are mediated by S-1-P1
receptors suggesting a link between G proteins and
PLC.13-15 The present study examines the G-protein path-
ways involved in PLC activation and oxygen free radical
generation and demonstrates that S-1-P induces time de-
pendent activation of PLC- through a G12/13 G
pathway, which in turn induces oxygen free radical gener-
ation. Inhibition of PLC- will block oxygen free radical
generation, MAPK activation, and vascular smooth muscle
cell migration in response to S-1-P.
There are a multitude of pathways in the cell, and many
are redundant. However, membrane events are a choke
point in these processes, and both G-protein–coupled re-
ceptors and receptor-linked tyrosine kinases appear to be
important therapeutic targets to moderate cell behavior.
The receptor-regulated PLC- pathway is an important
component in signaling cascades that regulate many cell
functions; it can be activated by both G-protein coupled
receptor agonists (eg, S-1-P, angiotensin II, or bradykinin)
and by receptor-linked tyrosine kinase agonists (eg, platelet-
derived growth factor).16
PLC- exists as a dimer within the cell and can interact
with Gq and G12/13 G-proteins.17 We have demon-
strated that both are present in the VSMC. These G-
proteins are part of a trimeric molecular complex with the
G and G G-proteins. G and G G-proteins are tightly
associated. PLC-1 and PLC- are expressed in human and
rat aortic vascular smooth muscle cells. PLC-1 appears to
be the isoform critical for angiotensin II–regulated PLC-
signaling in VSMC.18 S-1-P signaling shares many similar-
ities with angiotensin II signaling. Our data show that
PLC- and PLC- can be activated by S-1-P in a time-
dependent manner and that PLC- activity in response to
S-1-P is mediated by both G12/13 and G proteins and
can modulate VSMC migration. Neither Gi nor Gq
appear to be involved.
Consistent with these findings, S-1-P has previously
been shown to activate G12/13 and stimulate PLC-1
and PLC-3 and that this activity was partially inhibited by
G antibodies.19 The receptor S-1-P2 has also been linked
to activation of PLC- via G subunits.20 We have previ-
ously shown that the VSMC express S-I-P1, S-1-P2, and
S-1-P3 receptors.4 In this report, we show a similar effect
on PLC- activation using the G inhibitor -	RKCT.
Silencing of the receptor S-1-P2 but not receptor S-1-P1receptors abolishes activation of Gq, G12/13, and
Gi2, and suppresses S-1-P–stimulated PLC-. The selec-
tive S-1-P1 receptor agonist, SEW2871, was found not to
stimulate PLC- activity, further supporting the hypothesis
that S-1-P2 receptors may be the principal S-1-P receptor
leading to activation of PLC-.20
We have previously demonstrated that S-1-P can in-
duce ERK1/2 and p38MAPK activation and that these
events were Gi-mediated and that PI3-K was involved.4,6
The present report suggests that PLC- is also involved in
the upstream mediation of ERK1/2 and p38MAPK. A sim-
ilar finding has been seen with the G-protein–coupled
receptor agonist angiotensin II.21 Angiotensin II–medi-
ated MAPK activation is also regulated by the generation of
reactive oxygen species derived from NAD(P)H oxidases,
which is in part mediated by PLC.22 The present data set
demonstrates that PLC- plays a role in S-1-P–mediated
oxygen free radical generation in VSMCs. Evidence of the
importance of S-1-P and oxygen free radicals has been
shown in physiologic preparations of VSMCs.
One part of the restenosis process is constrictive remod-
eling where the vessel appears to heal by constriction that
reduces the effective luminal diameter. Keller et al23 exam-
ined myogenic vasoconstriction in SMCs and found that it
required the activation of sphingosine kinase (the enzyme
that produces S-1-P) and the generation of oxygen free
radicals. The rapid and transient production of oxygen free
radicals was enhanced by expression of wild-type sphin-
gosine kinase and inhibited by a dominant-negative mu-
tant. Exogenous S-1-P was also able to induce oxygen free
radical production. Chemical (DPI), peptide (gp91ds-tat/
gp91ds), and genetic (N17Rac) inhibition strategies
against NAD(P)H oxidase indicated that NAD(P)H oxi-
dase was the likely source of the oxygen free radicals de-
tected in response to S-1-P.23 This data set is consistent
with our data on S-1-P–mediated oxygen free radical gen-
eration likely from NAD(P)H oxidase and that we can
inhibit DHE staining and S-1-P–mediated migration with
DPI.
We have demonstrated that inhibition of PLC- will
attenuate oxygen free radical generation and downstream
MAPK activation. Arterial injury will also induce an imme-
diate profound vascular oxidative stress, likely accounted
for by activation of vessel wall NAD(P)H oxidase.24,25
Superoxide production increases significantly 24 hours
after balloon-induced injury. These changes appear
NAD(P)H oxidase–dependent and are associated with
augmented NAD(P)H oxidase activity and upregulation of
p47(phox) and p67(phox).26 One can speculate that the
platelet-rich thrombus present on the surface provides a
rich source of S-1-P that could increase oxygen free radical
production in a manner similar to that described by Keller
et al.23
Diabetes mellitus is also a disease with an oxidative
component. It has recently been reported that S-1-P pre-
vents monocyte adhesion to the aortas of type 1 diabetic
mice. Activation of the receptor S-1-P1 on endothelium by
S-1-P decreases nuclear factor-
B nuclear translocation and
JOURNAL OF VASCULAR SURGERY
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sion.27 It thus appears that S-1-P and oxygen free radical
production are important in a vessel’s response to injury.
The present data set suggests that S-1-P can mediate these
effects through G-proteins and PLC-.
CONCLUSION
S-1-P can induce oxygen free radical generation
through a G12/13–G, PLC-–mediated mechanism,
which facilitates VSMC MAPK activation and cell migra-
tion. To our knowledge, this is the first description of
PLC-mediated oxygen free radical generation as a mediator
of S-1-P VSMC migration and illustrates the need for the
definition of cell signaling to allow targeted molecular
strategies designed to modulate vessel remodeling and
prevent restenosis.
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Materials. D-erythro-sphingosine-1-phosphate was
purchased from Avanti Polar-Lipids (Alabaster, Ala). Per-
tussis toxin was purchased from Sigma Chemical Co (St
Louis, Mo). GP-2A was purchased from Biomol (Ply-
mouth Meeting, Penn). U73122 (U7), the inactive analog
U73343, and PD98059 were purchased from Calbiochem
(La Jolla, Calif). Small interfering RNA to Gi2 and Gi2,
Gq, and G12/13 were purchased from (Ambion, Inc
Austin, Tex). Empty adenovirus and adenoviral COOH-
terminus -adrenergic receptor kinase were purchased
from Weigen Inc. Peroxidase-conjugated antirabbit immu-
noglobulin G (IgG) antibody (raised in goat) and peroxi-dase-conjugated antimouse IgG antibody (raised in goat)
were purchased from Jackson ImmunoResearch Laborato-
ries (West Grove, Pa). Phospho-extracellular signal-regu-
lated kinases 1/2 (ERK1/2) antibody was purchased from
Promega, Inc (Madison, Wis). Total ERK 1/2 antibody was
purchased from BD Transduction Laboratories (Lexington,
Ky). Phospho-p38MAPK antibody was purchased from Bio-
source (Camarillo, Calif). Total p38MAPK mitogen-activated
protein kinase, phospho-MEK1/2 (ser217/221), and phos-
pho-MKK3/6 (ser189/207) antibodies were purchased
from Cell Signaling (Beverley, Mass). Dulbecco minimal es-
sential medium (DMEM) and Dulbecco phosphate buffered
saline (DPBS) were purchased from Cellgro (Herndon, Va).
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Volume 46, Number 6 Roztocil, Nicholl, and Davies 1259.e2Fig E1 (online only). Western blots of small interfering RNA (si
RNA) for G-proteins. We examined the expression of the G-
proteins in the presence of specific siRNA to Gi2, Gi3, Gq, and
G12/13 after performing concentration-dependent suppression
experiments. Western blots of Gi2, Gi3, Gq, and G12/13,
are shown in the presence of each siRNA used and the scrambled
siRNA control. There is effective downregulation of each G-
protein with the respective G-protein siRNA without affecting
other G-proteins. We have also added Gs and -actin as loading
controls.Fig E2 (online only). Oxygen free radical production: sphin-
gosine-1-phosphate (S-1-P; 0.1M)–induced oxygen free radical
production as measured by quantitative dihydroethidium staining
was significantly inhibited by U7 (10nM) but not by InactiveU7
(10nM). Representative photographs of the staining are shown.A,
Dulbecco minimal essential medium (DMEM); (B) S-1-P; (C)
S-1-P with InactiveU7; and (D) S-1-P with U7). E, The bar chart
shows the quantification of the experiment A to D. F, The bar
chart shows oxygen free radical production in response to angio-
tensin II and S-1-P in the presence and absence of absence of the
nicotinamide dinucleotide phosphate hydrogen oxidase inhibitor,
diphenyleneiodonium chloride (DPI; 10M), as measured by
quantitative dihydroethidium staining. Values are the mean 
SEM (n  6). *P  .05; **P  0.01 compared with control.
JOURNAL OF VASCULAR SURGERY
December 20071259.e3 Roztocil, Nicholl, and DaviesFig E3 (online only). Mitogen-activated protein kinase (MAPK) and phospholipase C- (PLC-). A, The presence
of U7 (10nM) attenuated sphingosine-1-phosphate (S-1-P; 0.1M)–mediated (ERK1/2) and (B) p38MAPK activation
but (C) had no effect on akt activation as measured by Western blotting. The presence of InactiveU7 (10nM) had no
effect, and the results could be superimposed on the control curves. D, A representative Western blot of the maximum
response for each kinase is shown. Both activated and total protein expression is shown. Values are the mean  SEM
of the ratio of the phosphorylation of the respective protein relative to the total unphosphorylated protein (n 6). *P
 .05 compared with control. DMEM, Dulbecco minimal essential medium.
